Huizhou Medicine Institute

Huizhou, China

Huizhou Medicine Institute

Huizhou, China
SEARCH FILTERS
Time filter
Source Type

Xiao Z.,Southern Medical University | Xiao Z.,Guangdong Provincial Key Laboratory of Gastroenterology | Li B.,Southern Medical University | Li B.,Huizhou First Hospital | And 12 more authors.
Clinica Chimica Acta | Year: 2014

Background: Methylation-sensitive high-resolution melting (MS-HRM) is a new technique for assaying DNA methylation, but its feasibility for assaying stool in patients with colorectal cancer (CRC) is unknown. Methods: First, the MS-HRM and methylation-specific PCR (MSP) detection limits were tested. Second, the methylation statuses of SFRP2 and VIM were analyzed in stool samples by MS-HRM, and in matching tumor and normal colon tissues via bisulfite sequencing PCR (BSP). Third, a case-control study evaluated the diagnostic sensitivity and specificity of MS-HRM relative to results obtained with MSP and the fecal immunochemical test (FIT). Finally, the linearity and reproducibility of MS-HRM were assessed. Results: The detection limits of MS-HRM and MSP were 1% and 5%, respectively. The diagnostic sensitivities of MS-HRM (87.3%, 55/63) in stool and BSP in matching tumor tissue (92.1%, 58/63) were highly consistent (κ=0.744). The MS-HRM assay detected 92.5% (37/40) methylation in CRCs, 94.4% (34/36) in advanced adenomas, and 8.8% (5/57) in normal controls. The results of MS-HRM analysis were stable and reliable and showed fairly good linearity for both SFRP2 (P<0.001, R2=0.957) and VIM (P<0.001, R2=0.954). Conclusions: MS-HRM shows potential for CRC screening. © 2014 Elsevier B.V.


Huang B.-T.,Inner Mongolia Medical College | Zeng Q.-C.,Guangdong Medical College | Yu J.,Aurora University | Xiao Z.,Inner Mongolia Medical College | And 3 more authors.
Journal of Cancer Research and Clinical Oncology | Year: 2012

Background: In international prognostic index (IPI) risktailored adult patients with diVuse large B-cell lymphoma (DLBCL), it is still unclear whether the addition of maintenance rituximab (MR) improves progression-free (PFS) and overall survival (OS), after RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. Methods: In our study, 207 patients (age: 21-59 years) received six 14-day cycles of RCHOP and gained overall response. After RCHOP, 98 patients were enrolled in the observation (OBS) arm. 109 patients continued to receive MR therapy. Results: In IPI risk <2 proWle, PFS at 5 years reached 72.9% (MR arm) versus 56% (OBS arm) (P = 0.033). In IPI risk ≥2 proWle, PFS estimation at 5 years was 44.9% (MR arm) versus 33.5% (OBS arm) (P = 0.006). It is noteworthy that patients with IPI ≥2 who received MR achieved PFS similar to that for patients in the OBS arm with the IPI <2, 44.9% versus 56% (P = 0.97). In patients with an IPI <2, OS at 5 years was 83.2% (MR arm) versus 81.2% (OBS arm) (P = 0.708). In patients with an IPI ≥2, 5-year OS estimation was 44.6% (MR arm) versus 40.5% (OBS arm) (P = 0.067). Subgroup analysis of patients with an IPI ≥3 risk proWle shows a survival beneWt for patients receiving MR. OS at 5 years was 62% (MR arm) versus 49% (OBS arm), (P = 0.033). Conclusions In conclusion, maintenance rituximab after RCHOP improves progression-free survival. In addition, overall survival is improved for patients with an IPI 3 risk proWle receiving MR. © 2011 Springer-Verlag.


Huang B.-T.,Inner Mongolia Medical College | Zeng Q.-C.,Guangdong Medical College | Gurung A.,University of Colorado at Denver | Zhao W.-H.,Inner Mongolia Medical College | And 2 more authors.
Medical Oncology | Year: 2012

The purpose of the study was to evaluate eventfree survival (EFS), overall survival (OS) and safety for early addition of arsenic trioxide (As 2O3) as frontline consolidation therapy compared to high-dose arabinoside (HiDAC) in adult patients with de novo acute promyelocytic leukemia (APL). 271 patients (aged 17-65 years) received consolidation therapy containing As2O3 (two 21-day courses) or HiDAC regimen. EFS at 5 years was 75% versus 54% (P < 0.001), and OS at 5 years was 83% versus 71% (P = 0.002) in As2O3 and HiDAC treatment arms. 139 patients treated with As2O3, EFS at 5 years reached 79% versus 56% (P = 0.014), but OS at 5 years was 77% versus 84% (P = 0.32) in low-risk (WBC ≤ 10 × 109/L) and high-risk (WBC > 10 × 109/L) cohorts. Further, patients treated with As 2O3 rarely incurred agranulocytosis (1.4%, P < 0.001), or severe infection (0.7%, P < 0.001). It is still very well tolerated compared to HiDAC. We confirmed that As2O3 as a first-line consolidation regimen provided significant benefits of OS to patients with APL. The As2O3 regimen made low-risk patients gain more EFS benefits than high-risk group. The high-risk cohort receiving As 2O3 overcame the negative impact, yielding OS similar to that for with the low-risk patients treated with As2O3. Copyright © Springer Science+Business Media, LLC 2011.


Zhao W.-H.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | Huang B.-T.,Inner Mongolia University | Li B.-S.,Huizhou Medicine Institute | Chen R.-L.,Guangzhou University
Leukemia Research | Year: 2015

Objective: The open-label, prospective, observational study aimed to evaluate whether decitabine (DAC) plus thalidomide versus DAC monotherapy improved progression-free (PFS), overall survival (OS) and acute myeloid leukemia-free survival (AML-FS) for risk-tailored elderly patients with myelodysplastic syndromes (MDS). Method: Enrolled 107 patients (age: 65-82 years) received DAC (52/107) or DAC plus thalidomide (55/107) therapy for MDS. Results: 35/52 patients (67.3%) with DAC therapy reached overall response (OR), compared with 36/55 patients (65.5%) in DAC. +. thalidomide regimen (. P>. 0.05). DAC. +. thalidomide administered did not gain more profits of PFS and OS than DAC monotherapy. Risk-tailored analysis showed that DAC. +. thalidomide therapy did not enhance PFS (48.9% versus 42.8%, P>. 0.05) and OS (78.6% versus 71.2%, P>. 0.05) when compared with simple DAC regimen. Nevertheless, DAC. +. thalidomide markedly improved OS over DAC monotherapy (50.6% versus 40.2%, P<. 0.05) in high risk profile. Meanwhile, low risk group was superior to high risk group in AML-FS (57.2% versus 21.3%, P<. 0.01), but DAC. +. thalidomide still did not prolong 2-year AML-FS when compared with DAC (32.4% versus 27.8%, P<. 0.05). Moreover, thalidomide had a favorable toxicity profile as a single agent. In comparison with DAC monotherapy, the DAC. +. thalidomide regimen was relatively well tolerated. There was no severe non-hematological toxicity appearing in elderly patients with MDS. Conclusions: The study demonstrated that DAC. +. thalidomide improved 2-year OS for high risk patients. Thalidomide's proven activity and low toxicity profile made it an alternative treatment option for risk-tailored elderly patients with MDS. © 2015 Elsevier Ltd.


Huang B.-T.,Inner Mongolia University | Tan Y.,Southern Medical University | Zhao W.-H.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | And 2 more authors.
Journal of Cancer Research and Clinical Oncology | Year: 2014

Background: This was an open-label, observational, prospective assessment. We conducted an analysis of the impact of bortezomib-based therapy (PAD: bortezomib, doxorubicin, high-dose dexamethasone vs. CBd: cyclophosphamide bortezomib, low-dose dexamethasone) on the survival rates and adverse events in elderly patients with newly diagnosed multiple myeloma (MM). Methods: Out of 303 patients, 128 received the PAD regimen and the other 175 patients received the CBd induction therapy (age 65-89 years). Baseline patient characteristics between the two cohorts were balanced in age (P = 0.69), international staging system (ISS) prognostic stages (P = 0.90), serum calcium (P = 0.70), and serum creatinine (P = 0.52). Results: Overall response (OS) after the induction chemotherapy was achieved in 214 of 303 patients (70.6 %), with no significant differences observed between the two treatment groups (71.9 vs. 69.7 %, P = 0.68). Patients with ISS stage 2 reached the same 5-year OS advantages compared to patients with ISS stage 1, because they received bortezomib-based PAD or CBd treatments. Patients receiving CBd protocol gained similar satisfactory progression-free survival (PFS) results when compared to the PAD regimen group: PFS at 5 years reached 58.2 versus 58.9 % (P = 0.85). Five-year OS in the CBd arm had significant advantages compared to the PAD group, 79.9 versus 49.9 % (P < 0.05). The overall safety profiles showed that 26 of 128 (20.3 %) patients died in the PAD arm, while 13 of 175 patients died (7.4 %) in the CBd group (P < 0.01). Similarly, the PAD arm had a higher serious infection rate than that of the CBd arm (39.2 vs. 13.1 %, P < 0.01). Conclusions: Bortezomib benefits elderly patients with newly diagnosed MM; they achieve satisfactory treatment responses and survival advantages. Further, patients treated with CBd have superior treatment advantages, with a predictable safety profile, when compared to the PAD regimen. © 2013 Springer-Verlag Berlin Heidelberg.


Huang B.-T.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | Zhao W.-H.,Inner Mongolia University | Li B.-S.,Huizhou Medicine Institute | Chen R.-L.,Guangzhou University
Medical Oncology | Year: 2014

This open-label, prospective, observational study aimed to evaluate disease-free survival (DFS), overall survival (OS), PML–RARα polymerase chain reaction (PCR) monitoring and safety in elderly patients with de novo acute promyelocytic leukemia (APL) who were treated with either arsenic trioxide (As2O3) or medium-dose cytosine arabinoside (MiDAC) as frontline consolidation regimens. A total of 167 patients (age ≥65 years old) received all-trans retinoic acid + daunorubicin as induction therapy. Of these patients, 22 died before attaining complete remission; the remaining 145 subjects received MiDAC- or As2O3-based consolidation therapy. As2O3 was superior to MiDAC for improving DFS and OS. This benefit appeared to result from the longer 5-year DFS (92.0 vs. 69.1 %, P < 0.01) and OS (94.5 vs. 79.7 %, P < 0.05) of As2O3 compared to MiDAC. PCR monitoring demonstrated that As2O3 promoted a lower positive rate than MiDAC (21.7 vs. 4.5 %, P < 0.05), but this treatment had no advantage for maintaining a low positive rate in the high-risk group. The most common life-threatening adverse drug effects in patients with MiDAC were platelet counts <25 × 109/L (85.7 %), leukocyte counts <1.0 × 109/L (81.4 %) and severe infection (84.3 %). In contrast, the As2O3 regimen rarely caused leukocyte counts <1.0 × 109/L (22.7 %, P < 0.01), platelet counts <25 × 109/L (37.3 %, P < 0.01) or severe infection (21.3 %, P < 0.01). These data confirm that MiDAC should not be added during the initial consolidation of patients with APL because this treatment is far less effective, particularly in patients with a low-risk profile, and far more toxic than As2O3. © 2014, Springer Science+Business Media New York.


Huang B.-T.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | Zhao W.-H.,Inner Mongolia University | Li B.-S.,Huizhou Medicine Institute | Chen R.-L.,Guangzhou University
Leukemia Research | Year: 2014

Objective: This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN α-2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation. Method: A total of 123 ET patients received IFNα-2b therapy with JAK2V617F positive or negative mutation; and 136 PV patients with JAK2V617F+ received IFNα-2b or hydroxyurea (HU) therapy according to random number assignment (ages 18-65 years old). Result: ET patients receiving IFN α-2b with JAK2V617F+ had a greater advantage in overall hematologic response (OHR) than JAK2V617F- (83.3% versus 61.4%, P<0.01). For PV patients with JAK2V617F+, IFN had no OHR superiority to HU (70.3% versus 70.8%, P>0.05), but which gained a greater satisfactory molecular response than HU (54.7% versus 19.4%, P<0.01). IFN significantly decreased the phlebotomy rate, which was better than HU for MPDs patients with OHR than HU (3.6% versus 65.7%, P<0.01). Furthermore, ET patients with JAK2V617F+ demonstrated a definite advantage over JAK2V617F- in five-year PFS (75.9% versus 47.6%, P<0.05). For PV patients with JAK2V617F+, IFN α-2b was superior to HU in five-year PFS (66.3% versus 46.7%, P<0.01). Moreover, IFN α-2b also contributed to improved vasomotor symptoms in MPDs, and especially significantly decreased the incidence of distal paresthesias (14.1% versus 37.5%) and erythromelalgia (9.4% versus 29.2%) better than HU (P<0.01). Meanwhile, IFN did not observe the severe hematological adverse events in patients with PV or ET. Conclusion: The data confirmed that IFN α-2b benefited the patients with ET or PV, particularly for JAK2V617F+ mutation. © 2014 Elsevier Ltd.


Huang B.-T.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | Zhao W.-H.,Inner Mongolia University | Li B.-S.,Huizhou Medicine Institute | Chen R.-L.,Guangzhou University
Medical Oncology | Year: 2014

The open-label, prospective, observational study aimed to evaluate whether the addition of maintenance rituximab (MR) improved progression-free survival (PFS) and overall survival (OS), after fludarabine, cyclophosphamide, and rituximab (FCR) for cytogenetic risktailored elderly patients with chronic lymphocytic leukemia (CLL). Enrolled 201 patients (ages 65-84 years) who received FCR and gained an overall response. One hundred and four of 201 patients were in the observation (OBS) arm while 97/201 patients continued to receive MR therapy. After FCR, no more benefits were provided by MR versus OBS in cytogenetic better intermediate-risk cohort. PFS at 10 years reached 68.6 versus 58.1% (P > 0.05). Ten-year OS was 81.8 versus 74.6% (P > 0.05). However, the improvement of PFS and OS were as dramatic as the improvements of being MR treating versus OBS mainly in the poor-risk cohort. PFS at 10 years reached 57.1 versus 22.7% ( P < 0.01), and 10-year OS was 71.2 versus 41.7% (P < 0.01). Compared with OBS, no severe hematologic adverse events (AEs) (Grades 3-4) appeared in patients with MR; only some mild non-hematologic AEs incurred (nausea-vomiting 0.96%, allergy 1.9% and infection 1.9%) during the maintenance treatment. The study showed that MR improved 10-year RFS and OS for cytogenetic poor-risk patients with CLL. © Springer Science+Business Media 2014.


Huang B.-T.,Inner Mongolia University | Zhao W.-H.,Inner Mongolia University | Zeng Q.-C.,Southern Medical University | Li B.-S.,Huizhou Medicine Institute | Chen R.-L.,Guangzhou Medical College
Medical Oncology | Year: 2014

The open-label, prospective study aimed to evaluate the efficacy and safety for standard intensive chemotherapy compared with attenuated therapy in elderly patients with acute myeloid leukemia (AML). A total of 297 patients between 65 and 82 years were enrolled in the study. The 141 patients received standard-dose therapy (daunorubicin 45 mg/m2 × 3 days with cytarabine 100 mg/m2 × 7 days for induction therapy, while post-induction therapy consisted of high-dose cytarabine 1.5 g/m2 × 4 days), and the attenuated treatment (daunorubicin 30 mg/m2 × 3 days with cytarabine 75 mg/m2 × 7 days for induction therapy, while post-induction therapy consisted of attenuated high-dose Ara-C 1.0 g/m2 × 3 days) was administered to the remaining 156 patients, based on a random number assigned. Total 168 patients (56.6 %) achieved complete remission with an incomplete blood recovery (CR)/CRi. No significant differences were observed between the two treatments (P = 0.60). Attenuated chemotherapy improved overall survival (OS) and progression-free survival (PFS) compared to standard-dose therapy; 5-year OS values for these two groups were 39 and 24 months, respectively (P < 0.001), and the PFS values for these two groups were 35 versus 23 months (P < 0.001). In addition, the attenuated treatment with a poor risk profile overcame the negative impact and yielded OS and PFS values similar to those of the standard-dose chemotherapy with a better-to-intermediate risk profile. Five-year OS values for these two groups were 28 versus 28 months (P = 0.89), and the 5-year PFS values were 27 and 28 months, respectively (P = 0.89). The most common adverse drug effect for chemotherapy was agranulocytosis (98.3 %). There was a significant difference in early mortality between the attenuated and standard-dose treatment groups (0.64 % vs. 7.1 %, respectively, P < 0.01). Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with AML. © 2014, Springer Science+Business Media New York.


PubMed | Huizhou Medicine Institute, Inner Mongolia University, Southern Medical University and Guangzhou University
Type: Comparative Study | Journal: Leukemia research | Year: 2015

The open-label, prospective, observational study aimed to evaluate whether decitabine (DAC) plus thalidomide versus DAC monotherapy improved progression-free (PFS), overall survival (OS) and acute myeloid leukemia-free survival (AML-FS) for risk-tailored elderly patients with myelodysplastic syndromes (MDS).Enrolled 107 patients (age: 65-82 years) received DAC (52/107) or DAC plus thalidomide (55/107) therapy for MDS.35/52 patients (67.3%) with DAC therapy reached overall response (OR), compared with 36/55 patients (65.5%) in DAC+thalidomide regimen (P>0.05). DAC+thalidomide administered did not gain more profits of PFS and OS than DAC monotherapy. Risk-tailored analysis showed that DAC+thalidomide therapy did not enhance PFS (48.9% versus 42.8%, P>0.05) and OS (78.6% versus 71.2%, P>0.05) when compared with simple DAC regimen. Nevertheless, DAC+thalidomide markedly improved OS over DAC monotherapy (50.6% versus 40.2%, P<0.05) in high risk profile. Meanwhile, low risk group was superior to high risk group in AML-FS (57.2% versus 21.3%, P<0.01), but DAC+thalidomide still did not prolong 2-year AML-FS when compared with DAC (32.4% versus 27.8%, P<0.05). Moreover, thalidomide had a favorable toxicity profile as a single agent. In comparison with DAC monotherapy, the DAC+thalidomide regimen was relatively well tolerated. There was no severe non-hematological toxicity appearing in elderly patients with MDS.The study demonstrated that DAC+thalidomide improved 2-year OS for high risk patients. Thalidomides proven activity and low toxicity profile made it an alternative treatment option for risk-tailored elderly patients with MDS.

Loading Huizhou Medicine Institute collaborators
Loading Huizhou Medicine Institute collaborators